Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of systemic and cerebral hemodynamics after systematic and early extracorporeal cardiopulmonary resuscitation in swine.

Resuscitation plus·2026
Same author

Deleterious Effects of Liberal Fluid Therapy During Extracorporeal Cardiopulmonary Resuscitation in a Porcine Model of Prolonged Cardiac Arrest.

Journal of the American Heart Association·2026
Same author

Management of post-resuscitation vasoplegic shock: targets, strategies and outcomes.

Critical care (London, England)·2025
Same author

Multi-lens ultrasound arrays enable large scale three-dimensional micro-vascularization characterization over whole organs.

Nature communications·2025
Same author

Total liquid ventilation in a porcine model of severe acute respiratory distress syndrome using a new generation of liquid ventilator.

Intensive care medicine experimental·2025
Same author

Optimising fluid therapy during venoarterial extracorporeal membrane oxygenation: current evidence and future directions.

Annals of intensive care·2025

Related Experiment Video

Updated: Jul 10, 2026

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Making the heart resistant to infarction: how can we further decrease infarct size?

Renaud Tissier1, Alain Berdeaux, Bijan Ghaleh

  • 1INSERM, Unite 841, Creteil, F-94000 France.

Frontiers in Bioscience : a Journal and Virtual Library
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

New cardioprotective strategies target the Reperfusion Injury Salvage Kinase (RISK) pathway to reduce heart damage after acute myocardial infarction (AMI). These approaches, including pharmacological agents and myocardial cooling, aim to improve outcomes beyond standard reperfusion therapy.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

Related Experiment Videos

Last Updated: Jul 10, 2026

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Acute myocardial infarction (AMI) is a leading cause of death globally.
  • Current treatment relies on reperfusion therapy, with limited options for further myocardial salvage.
  • The Reperfusion Injury Salvage Kinase (RISK) pathway has emerged as a novel target for cardioprotection.

Purpose of the Study:

  • To review the efficacy of emerging cardioprotective strategies for acute myocardial infarction.
  • To explore interventions targeting the RISK pathway and adverse reperfusion events.
  • To evaluate the potential of myocardial cooling as an anti-infarct intervention.

Main Methods:

  • Review of existing literature on cardioprotective agents and strategies.
  • Analysis of mechanisms involving the RISK pathway, preconditioning, and postconditioning.
  • Examination of interventions aimed at mitigating reperfusion injury, such as calcium overload and free radical damage.

Main Results:

  • The RISK pathway plays a crucial role in mediating cardioprotection.
  • Pharmacological interventions activating the RISK pathway show promise.
  • Strategies addressing reperfusion injury and myocardial cooling are under investigation for improved efficacy.

Conclusions:

  • Activating the RISK pathway offers a promising therapeutic avenue for reducing infarct size in AMI.
  • Novel pharmacological agents and myocardial cooling represent potential advancements in anti-infarct therapy.
  • Further clinical trials are needed to confirm the efficacy of these strategies in improving patient outcomes.